Cyclacel Pharmaceuticals, Inc. financial data

Symbol
CYCC, CYCCP on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
XCYTE THERAPIES INC (to 3/24/2006)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 97.7 % -70.3%
Debt-to-equity 864 % +1705%
Return On Equity -1.89K % -1009%
Return On Assets -196 % -105%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.97M shares -84.4%
Common Stock, Shares, Outstanding 1.81M shares -85.7%
Entity Public Float 5.62M USD -51%
Common Stock, Value, Issued 2K USD -77.8%
Weighted Average Number of Shares Outstanding, Basic 12.6M shares +23.8%
Weighted Average Number of Shares Outstanding, Diluted 12.6M shares +23.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6M USD -36.9%
Operating Income (Loss) -20.2M USD +29.3%
Nonoperating Income (Expense) -158K USD -154%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.4M USD +28%
Income Tax Expense (Benefit) -2.86M USD +36.5%
Net Income (Loss) Attributable to Parent -17.5M USD +26.3%
Earnings Per Share, Basic -1.93 USD/shares -1.05%
Earnings Per Share, Diluted -2.27 USD/shares +67.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6M USD -41%
Other Assets, Current 300K USD -86.3%
Assets, Current 7.71M USD -49.6%
Property, Plant and Equipment, Net 5K USD -79.2%
Operating Lease, Right-of-Use Asset 65K USD -47.6%
Assets 8.19M USD -51.8%
Accounts Payable, Current 4.74M USD +119%
Accrued Liabilities, Current 2.45M USD -47.9%
Liabilities, Current 7.19M USD +4.68%
Operating Lease, Liability, Noncurrent 5K USD -92.4%
Liabilities 7.19M USD +3.75%
Accumulated Other Comprehensive Income (Loss), Net of Tax -915K USD +16.6%
Retained Earnings (Accumulated Deficit) -434M USD -4.2%
Stockholders' Equity Attributable to Parent 999K USD -85%
Liabilities and Equity 8.19M USD -51.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -483K USD +93%
Net Cash Provided by (Used in) Financing Activities -79K USD -58%
Net Cash Provided by (Used in) Investing Activities -6K USD -50%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.81M shares -85.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -580K USD +91.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6M USD -41%
Deferred Tax Assets, Valuation Allowance 57.3M USD +7.54%
Deferred Tax Assets, Gross 57.3M USD +7.54%
Operating Lease, Liability 65K USD
Depreciation 2K USD -75%
Payments to Acquire Property, Plant, and Equipment 6K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.3M USD +26.6%
Lessee, Operating Lease, Liability, to be Paid 71K USD -50%
Property, Plant and Equipment, Gross 429K USD +3.37%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38K USD -41.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 38K USD -42.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 38K USD
Deferred Tax Assets, Operating Loss Carryforwards 57.1M USD +7.5%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 19K USD +7.96%
Additional Paid in Capital 436M USD +2.75%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.11M USD -28.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%